IDEAYA Biosciences Doses First Patient in a Phase 1 Combination Study of IDE196 and Crizotinib, a cMET Inhibitor

On January 5, 2021 IDEAYA Biosciences, Inc. (Nasdaq:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics, reported First-Patient-In (FPI) in the Phase 1 combination study of IDE196 and crizotinib, a cMET inhibitor, in metastatic uveal melanoma (MUM) (Press release, Ideaya Biosciences, JAN 5, 2021, View Source [SID1234573524]). The clinical combination of IDE196 and crizotinib is being evaluated by IDEAYA in collaboration with Pfizer pursuant to a clinical trial collaboration and supply agreement.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"IDEAYA is executing on its clinical trial strategy to evaluate IDE196 combination therapies in Metastatic Uveal Melanoma (MUM). We identified cMET as a potential combination agent through our translational research, including evaluation of cMET expression in MUM patient clinical samples from an IDE196 Phase 1 clinical trial and preclinical demonstration of synergy between IDE196 and crizotinib, going from bench to bedside in approximately one year," said Mick O’Quigley, Vice President, Head of Development Operations. IDEAYA plans to present preclinical translational data supporting the IDE196/crizotinib combination therapy in H1 2021.

"IDEAYA’s clinical trials evaluating IDE196 plus either crizotinib or binimetinib as combination therapies are each based on compelling biological rationale for treating patients with metastatic uveal melanoma – a solid tumor for which there is a high unmet medical need and currently no approved therapies," said Meredith McKean, MD, MPH, Associate Director, Melanoma and Skin Cancer Research Program, Sarah Cannon Research Institute at Tennessee Oncology.